A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, ...

Allogeneic CAR-T cell therapy is produced using CRISPR gene editing from cells donated by healthy individuals.

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results ...

Intermountain Health is now offering a national first-of-its kind expansion of CAR-T Cell Therapy, bringing cutting-edge cancer care closer to patients in ...

Vadodara: Alembic Pharmaceuticals Limited has announced that the company has received final approval from the US Food & Drug ...

DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...

Making CAR T Vision a reality will require the coming together of a complex ecosystem of partners, each with their own unique role to play. To learn more about CAR T Vision, review the roadmap report ...

Due to financial, logistical, and regulatory barriers, only two in 10 patients eligible for CAR T-cell therapy in the US ...

Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma ...

Labcorp , a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio. The additions include new test offerings for solid ...